Cetafor 2000 mg IV

Form: IV injection/infusion
Dosage: 2000 mg
Packaging: Powder for solution for IV injection/infusion

Active substance:  ceftriaxone (injectable 3rd generation cephalosporin)

Form: 2000 mg powder for solution for injection (IV injection -perfusion)

Other available forms of Cetafor

Cetafor® 500 IV: ceftriaxone 500 mg + solvent (water for injection 5 ml)

Cetafor® 1000 IV: ceftriaxone 1000 mg + solvent (water for injection 10 ml)

Cetafor® 1000 IM: ceftriaxone 1000 mg + solvent (lidocaïne 1% 4 ml)

Packaging: Box with one powder vial

Target: adults and children (including in term neonates)

Cetafor is indicated for the treatment of the following infections in adults and children

including term neonates (from birth):

  • Bacterial Meningitis
  • Community acquired pneumonia
  • Hospital acquired pneumonia
  • Acute otitis media
  • Intra-abdominal infections
  • Complicated urinary tract infections (including pyelonephritis)
  • Infections of bones and joints
  • Complicated skin and soft tissue infections
  • Gonorrhoea
  • Syphilis
  • Bacterial endocarditis

Cetafor may be used:

  • For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults
  • For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age
  • For Pre-operative prophylaxis of surgical site infections
  • In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection
  • In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Cetafor should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.

The dose of Cetafor depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.

 The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for 48 – 72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.

IV form

IV bolus injection :

Cetafor® IV (500 mg, 1000 mg and 2000 mg) should be administered by intravenous injection. For Cetafor 500 mg and Cetafor 1000 mg the solution is prepared with the 5 ml/10 ml/20 ml ampoule supplied in the same box.

For Cetafor 2000 mg: dissolve the product in 20 ml of water for injection

The solution should be administered directly after reconstitution by the IV route over a period of 2.5 minutes per 5 ml.

IV infusion

For IV infusion, Cetafor 2000 IV is dissolved in 40 ml of one of the following calciumfree infusion fluids: sodium chloride 0.9%, sodium chloride 0.45% + dextrose 2.5%, dextrose 5%, dextrose 10%, dextran 6% in dextrose 5%, hydroxyethyl-starch 6-10%, water for injections. The infusion should be administered over at least 30 minutes.

When adding 40ml of water for injections, the final concentration of the reconstituted solution is 48.34 mg/ml. In neonates, intravenous doses should be given over 60 minutes to reduce potential risk of bilirubin encephalopathy.

All these solutions should be administered immediately after reconstitution.

Solutions containing ceftriaxone should not be mixed or added to other agents. In particular, ceftriaxone is not compatible with calcium-containing solutions such as Hartmann’s solution and Ringer’s solution. Ceftriaxone should not be mixed or administered simultaneously with solutions containing calcium.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma